
Opinion|Videos|January 17, 2025
MAIC Analyses and Bispecific Therapies: Guiding Treatment Decisions in B-Cell Lymphomas
Panelists discuss how comparative data from matching-adjusted indirect comparison (MAIC) analyses guide treatment decisions between bispecific therapies and the insights from MAIC results comparing epcoritamab and glofitamab that may influence therapy selection.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- How do you use comparative data from MAIC analyses to guide treatment decisions between available bispecific therapies?
- What do the results of the MAIC comparing epcoritamab and glofitamab suggest about the relative differences of these agents, and how might these influence therapy selection?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Nerandomilast for Idiopathic Pulmonary Fibrosis
2
Amgen Direct-to-Patient Program Aims to Expand Access to Evolocumab Amid US Drug Pricing Reforms
3
Cohere Health Findings on AI in Prior Authorization Conflict With AMA Data
4
Contributor: Why Public Health Keeps Failing—and How to Fix It
5